Notes to the Consolidated Financial Statements of the Bayer Group

Key Data by Segment

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

2016

2017

 

2016

2017

 

2016

2017

 

2016

2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

1

For definition, see Management Report & Annexes, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

2016 Group total including Covestro

Net sales (external)

 

16,420

16,847

 

6,037

5,862

 

9,915

9,577

 

1,523

1,571

Change1

 

+7.3%

+2.6%

 

−0.6%

−2.9%

 

−2.1%

−3.4%

 

+2.2%

+3.2%

Currency-adjusted change1

 

+8.7%

+4.3%

 

+3.5%

−1.7%

 

+0.2%

−2.2%

 

+4.8%

+4.1%

Intersegment sales

 

29

38

 

5

14

 

36

38

 

10

8

Net sales (total)

 

16,449

16,885

 

6,042

5,876

 

9,951

9,610

 

1,533

1,579

EBIT1

 

3,389

4,325

 

695

518

 

1,755

1,235

 

313

307

EBIT before special items1

 

3,947

4,665

 

987

818

 

1,898

1,643

 

320

338

EBITDA before special items1

 

5,251

5,711

 

1,411

1,231

 

2,421

2,043

 

349

381

ROCE1

 

16.2%

21.0%

 

3.5%

2.7%

 

12.9%

9.6%

 

63.5%

47.1%

Net cash provided by operating activities

 

3,368

3,867

 

874

1,059

 

2,071

1,884

 

193

209

Equity-method income (loss)

 

1

 

2

1

 

(1)

(1)

 

Equity-method carrying amounts2

 

3

3

 

11

11

 

15

35

 

Assets2

 

22,173

21,753

 

16,558

14,896

 

14,868

13,106

 

838

935

Capital expenditures2

 

851

1,126

 

220

181

 

773

670

 

39

41

Depreciation, amortization and impairments

 

1,695

1,251

 

601

627

 

525

481

 

30

45

of which impairment losses

 

464

217

 

175

213

 

52

72

 

1

9

of which impairment loss reversals

 

 

 

(1)

 

(1)

Research and development expenses

 

2,787

2,888

 

259

240

 

1,164

1,166

 

140

155

Key Data by Segment – continued

 

 

Reconciliation

 

 

 

 

 

All Other segments

 

Corporate Functions and Consolidation

 

Group

 

 

2016

2017

 

2016

2017

 

2016

2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2016 figures restated

1

For definition, see Management Report & Annexes, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

2016 Group total including Covestro

Net sales (external)

 

1,042

1,142

 

6

16

 

34,943

35,015

Change1

 

−5.0%

+9.6%

 

+50.0%

+166.7%

 

+2.5%

+0.2%

Currency-adjusted change1

 

−4.2%

+10.5%

 

 

+4.7%

+1.6%

Intersegment sales

 

1,356

2,324

 

(1,436)

(2,417)

 

Net sales (total)

 

2,398

3,466

 

(1,430)

(2,401)

 

34,943

35,015

EBIT1

 

(50)

4

 

(364)

(486)

 

5,738

5,903

EBIT before special items1

 

18

115

 

(344)

(449)

 

6,826

7,130

EBITDA before special items1

 

224

358

 

(338)

(436)

 

9,318

9,288

ROCE1

 

 

 

10.3%

10.8%

Net cash provided by operating activities

 

503

256

 

(574)

(664)

 

6,435

6,611

Equity-method income (loss)

 

 

(7)

19

 

(6)

20

Equity-method carrying amounts2

 

 

325

3,958

 

584

4,007

Assets2

 

2,632

2,206

 

15,986

22,191

 

82,238

75,087

Capital expenditures2

 

307

359

 

18

41

 

2,627

2,418

Depreciation, amortization and impairments

 

206

243

 

6

13

 

3,063

2,660

of which impairment losses

 

7

2

 

 

699

513

of which impairment loss reversals

 

 

 

(1)

(1)

Research and development expenses

 

39

3

 

16

52

 

4,405

4,504

Compare to Last Year